12-month results of coronary angioplasty and stenting using sirolimus- and everolimus-eluting stents

Poliakov R.S.; Saakian Iu.M.; Mardanian G.V.; Puretskiĭ M.V.; Pirkova A.A.; Naumov S.M.; Boltenkov A.V.; Abugov S.A.

doi:https://doi.org/

Poliakov R.S.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Saakian Iu.M.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Mardanian G.V.

FGBU RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Puretskiĭ M.V.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Pirkova A.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Naumov S.M.

FGBU RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Boltenkov A.V.

FGBU RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Abugov S.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

12-month results of coronary angioplasty and stenting using sirolimus- and everolimus-eluting stents

Authors:

Poliakov R.S., Saakian Iu.M., Mardanian G.V., Puretskiĭ M.V., Pirkova A.A., Naumov S.M., Boltenkov A.V., Abugov S.A.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(1): 4‑10

Read: 1740 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Poliakov RS, Saakian IuM, Mardanian GV, et al. 12-month results of coronary angioplasty and stenting using sirolimus- and everolimus-eluting stents. Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(1):4‑10. (In Russ.)

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Intranasal stents in endoscopic paranasal sinus surgery: a review of efficacy and safety. Russian Bulletin of Otorhinolaryngology. 2025;(5):100-107

Abstract:

Results of treatment were analyzed in 411 patients undergoing coronary angioplasty and stenting with drug-eluting stents. 199 patients with implanted everolimus-eluting stents (EES) were included in the group 1. 212 patients with implanted sirolimus-eluting stents (SES) were included in the control group 2. After 12 months of observation there were no any statistically significant differences between EES and SES groups in frequency of stent thrombosis (1.6% versus 4.6%, p=0.14), recurrent revascularizations (2.7% versus 5.1%, p=0.29), acute myocardial infarction (2.7% versus 4.6%, p=0.42) and lethal outcomes (2.1% versus 3.6%, p=0.54). Meanwhile application of EES was related to lesser amount of unfavorable cardiac events compared with SES (6.4% versus 12.8%, p=0.04)

Keywords:

coronary stenting

drug-eluting stents

sirolimus

everolimus

Authors:

Poliakov R.S.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Saakian Iu.M.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Mardanian G.V.

FGBU RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Puretskiĭ M.V.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Pirkova A.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Naumov S.M.

FGBU RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Boltenkov A.V.

FGBU RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Abugov S.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Close metadata

References:

de Waha A., Cassese S., Byrne R. et al. J Am Coll Cardiol 2012; 59: E1507.
Byrne R.A. Two-year outcomes after everolimus - or sirolimus-eluting stents in patients with coronary artery disease in the ISAR TEST 4 Trial. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.
Cutlip D., Windecker S., Mehran R. et al. ARC definitions of stent thrombosis. Circulation 2007; 115: 2344-2351.
Joner M., Finn A.V., Farb A. et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
Kandzari D.E., Leon M.B., Popma J.J. et al. Comparison of zotarolimuseluting and sirolimus-eluting stents in patients with native coronary artery disease. J Am Coll Cardiol 2006; 48: 2440-2447.
Kedhi E., Joesoef K.S., McFadden E. et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice. Lancet 2010; 375: 201-209.
Räber L., Jüni P., Nüesch E. et al. Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization. J Am Coll Cardiol 2011; 57: 21: 2143-2151.
Mehta S.R., Bassand J.P., Chrolavicius S. et al. CURRENT-OASIS 7 Investigators. N Engl J Med 2010; 363: 10: 930-942.
Morice M.C., Serruys P.W., Sousa J.E. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
Moses J.W., Leon M.B., Popma J.J. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
Onuma Y., Kukreja N., Piazza N. et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH registry. J Am Coll Cardiol 2009; 54: 269-276.
Räber L., Windecker S. Current status of drug-eluting stents. Cardiovasc Ther 2011; 29: 3: 176-189.
Rasmussen K., Maeng M., Kaltoft A. et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care. Lancet 2010; 375: 9720: 1090-1099.
Schampaert E., Cohen E.A., Schlüter M. et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).
Schofer J., Schlüter M., Gershlick A.H. et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (ESIRIUS). Lancet 2003; 362: 1093-1099.
Schomig A., Dibra A., Windecker S. et al. A metaanalysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1373-1380.
Serruys P.W., Kutryk M.J.B., Ong A.T.L. Coronary-artery stents.
Serruys P.W., Ruygrok P., Neuzner J. et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent. Euro Intervention 2006; 2: 286-294.
Sousa J.E., Costa M.A., Abizaid A. et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. Circulation 2001; 103: 192-195.
Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis. Lancet 2007; 370: 937-948.
Stone G.W., Ellis S.G., Cox D.A. et al., for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
Stone G.W., Midei M., Newman W. et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease. JAMA 2008; 299: 1903-1913.
Stone G.W., Rizvi A., Newman W. et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 18: 1663-1674.
Lüscher T.F., Steffel J., Eberli F.R. et al. Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications. Circulation 2007; 115: 1051-1058.